Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
The Medical Letter on Drugs and Therapeutics · 06.07.2026 · 68 (1758) · 105-106
DOI: 10.58347/tml.2026.1758a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.07.2026.
Abstract (Originalsprache)
The FDA has approved baxdrostat (Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension. The Medical Letter on Drugs and Therapeutics, 68(1758), 105-106. https://doi.org/10.58347/tml.2026.1758a
Vancouver
Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension. The Medical Letter on Drugs and Therapeutics. 2026;68(1758):105-106. doi:10.58347/tml.2026.1758a
BibTeX
@article{euvimed2026,
title = {Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1758},
pages = {105--106},
doi = {10.58347/tml.2026.1758a}
}
EUVIMED